Customized PTO/SB/21 (09-06)

TRANSMITTAL FORM

(for all correspondence after initial filing)

Total number of pages in this submission =

Application #	10/661,809
Confirmation #	7385
Filing Date	15 September 2003
First Inventor	HOOK et al
Art Unit	1631
Examiner	Smith, Carolyn L.
Docket #	P07741US01/BAS

ENCLOSURES *(check all that apply)*

- ☒ Fees calculated below
- ☒ Amendment/Reply
  - ☒ including Attachments
- ☐ **After Final** Amendment/Reply
  - ☐ including Attachment(s)
- ☒ Extension of Time Petition
- ☐
- ☐ Reply to Missing Parts/Incomplete Application
- ☐ Certified Copy of Priority Document(s)
- ☒ Information Disclosure Statement
- ☐ Drawing(s)
- ☐ Terminal Disclaimer
- ☐
- ☐

FEES CALCULATION: For claims if required and/or other fees as shown below:

	NOW	*Previously Paid For*	*Present Extra*	*Rate*	$
☒ TOTAL CLAIMS	39	- 40	0	X $ 50 =	0
☒ INDEPENDENT CLAIMS	6	- 4	2	X $ 200 =	400
				TOTAL OF ABOVE CLAIMS FEES =	400
☒ Reduction by ½ for **small entity status** of applicant					200
				SUBTOTAL =	200
☒ Fee for extension of time (per attached Petition)					510
☐ Other fee for					
				TOTAL OF ALL FEES =	**$710**

☒ Payment by credit card. FORM PTO-2038 in the amount of $710 is attached.

☒ The Director is authorized to charge any fee, additional fee or extension fee due in connection herewith to Deposit Account No. 12-0555:
(1) if no payment or an insufficient payment is enclosed and a fee is due in connection herewith; or
(2) if no petition for extension of time is enclosed but an EOT is required - and in this event, applicant hereby petitions under 37 CFR 1.136(a) for an extension of time of as many months as are required to render this submission timely.

Date: February 16, 2007

By: B. Aaron Schulman
Registration No.: 31,877

STITES & HARBISON PLLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314
TEL: 703-739-4900 • FAX: 703-739-9577 • Customer No. 00881

Addendum

Attachment 1

SYSTEM AND METHOD FOR OLAP REPORT GENERATION WITH SPREADSHEET REPORT WITHIN THE NETWORK USER INTERFACE

SYNOPSIS OF APPLICATION OF WRITTEN DESCRIPTION GUIDELINES

Contents

Example 16: Antibodies

Specification: The specification teaches that antigen X has been isolated and is useful for detection of HIV infections. The specification teaches antigen X as purified by gel filtration and provides characterization of the antigen as having a molecular weight of 55 KD. The specification also provides a clear protocol by which antigen X was isolated. The specification contemplates but does not teach in an example antibodies which specifically bind to antigen X and asserts that these antibodies can be used in immunoassays to detect HIV. The general knowledge in the art is such that antibodies are structurally well characterized. It is well known that all mammals produce antibodies and they exist in five isotypes, IgM, IgG, IgD, IgA and IgE. Antibodies contain an effector portion which is the constant region and a variable region that contains the antigen binding sites in the form of complementarity determining regions and the framework regions. The sequences of constant regions as well as the variable regions subgroups (framework regions) from a variety of species are known and published in the art. It is also well known that antibodies can be made against virtually any protein.

→ **Claim:** An isolated antibody capable of binding to antigen X.

Analysis:

A review of the full content of the specification indicates that antibodies which bind to antigen X are essential to the operation of the claimed invention. The level of skill and knowledge in the art of antibodies at the time of filing was such that production of antibodies against a well-

characterized antigen was conventional. This is a mature technology where the level of skill is high and advanced.

The claim is directed to any antibody which is capable of binding to antigen X.

A search of the prior art indicates that antigen X is novel and unobvious.

Considering the routine art-recognized method of making antibodies to fully characterized antigens, the well defined structural characteristics for the five classes of antibody, the functional characteristics of antibody binding, and the fact that the antibody technology is well developed and mature, one of skill in the art would have recognized that the spectrum of antibodies which bind to antigen X were implicitly disclosed as a result of the isolation of antigen X.

→ **Conclusion:** The disclosure meets the requirement under 35 USC 112 first paragraph as providing an adequate written description of the claimed invention.